Not surprised to see a management change. The deal with the largest bio-pharma in the world needs talented people to commercialize it.
From a LONG perspective this deal is HUGE. Orbimed is deferring interest payments for two years which IMO establishes the time line for when they think the AMGEN along with other contracts will start generating sufficient revenue.